Business News • PR NewsWire • Almirall Announces Regulatory Filing of linaclotide for the Treatment of Irritable Bowel Syndrome With Constipation in Europe

Almirall Announces Regulatory Filing of linaclotide for the Treatment of Irritable Bowel Syndrome With Constipation in Europe

Almirall Announces Regulatory Filing of linaclotide for the Treatment of Irritable Bowel Syndrome With Constipation in Europe

BARCELONA, Spain, September 29, 2011 /PRNewswire/ -- - Linaclotide has demonstrated statistically significant improvement in abdominal pain/discomfort and global relief of IBS-C symptoms in Phase III clinical trials [1,2] - IBS-C is a debilitating disease associated with reduced...

View More : http://www.prnewswire.com/news-releases/almirall-announces-regulatory-filing-of-linaclotide-for-the-treatment-of-irritab...

Releted News by prnewswire

100e suisses Tesla Roadster prend la route

NTT Com to Expand Cloud-based Enterprise Network Service Globally

Report Helps Consumers Choose Health Plans

Additional Analysis from Two-Year Sequel Study of QNEXA Featured at The 2011 Annual Scientific Meeting of The Obesity Society